The European Medicines Agency is looking to sublet its former headquarters in the financial district of London, after a British court ruled on Wednesday (20 February) that it cannot break its lease despite the UK’s withdrawal from the EU.
The smooth transition of the EU drug agency from London to Amsterdam is threatened by delays in the Netherlands, whose bid to win the agency may have been misleading, a top representative of Italian pharmaceuticals told EURACTIV.com.
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.
The competition for the European Medicines Agency is not a horse race but the first concrete, effective decision the EU has to make in the wake of Brexit - and one with long-lasting consequences. A responsible yet ambitious mindset is therefore in orde...